A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/21/2011	EP2397034A1 Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment
12/21/2011	EP2396660A2 Prediction of response to platinum-based therapy
12/21/2011	EP2396430A1 Template-independent ligation of single-stranded dna
12/21/2011	EP2396409A2 Synthetic rna-based agonists of tlr7
12/21/2011	EP2396407A1 C-cbl and antagonists thereof for the treatment and diagnosis of cancer
12/21/2011	EP2396365A2 Reducible polymers for non-viral gene delivery
12/21/2011	EP2396340A1 Carba-nucleoside analogs for antiviral treatment
12/21/2011	EP2396335A1 N-[(6-azabicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof
12/21/2011	EP2396334A1 N-[(2-azabicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof
12/21/2011	EP2396333A1 Triazolo [4,3-b]pyridazine derivatives and their uses for prostate cancer
12/21/2011	EP2396332A2 Novel salts of sitagliptin
12/21/2011	EP2396331A1 Fused pyrimidines as akt inhibitors
12/21/2011	EP2396330A1 Fused pyrimidines
12/21/2011	EP2396329A1 Compounds for the treatment of hepatitis c
12/21/2011	EP2396328A2 Toll-like receptor modulators and treatment of diseases
12/21/2011	EP2396327A1 Histamine h3 inverse agonists and antagonists and methods of use thereof
12/21/2011	EP2396326A1 Spiroindolinone pyridine derivative
12/21/2011	EP2396325A1 Derivatives of azaindoles as inhibitors of protein kinases abl and src
12/21/2011	EP2396324A1 Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines as kinase inhibitors
12/21/2011	EP2396323A1 Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
12/21/2011	EP2396322A1 2-morpholino-pyridoý3,2-d¨pyrimidines
12/21/2011	EP2396321A2 Compositions and methods for controlling nematodes
12/21/2011	EP2396320A1 3-benzofuranyl-indol-2-one derivatives substituted at the 3 position, preparation thereof, and therapeutic use thereof
12/21/2011	EP2396319A1 Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof
12/21/2011	EP2396317A1 Crystalline polymorphic form 631
12/21/2011	EP2396316A1 Quinazolinones as prolyl hydroxylase inhibitors
12/21/2011	EP2396315A1 Fused pyridine and pyrazine derivatives as kinase inhibitors
12/21/2011	EP2396313A1 Isotopologues of thalidomide
12/21/2011	EP2396312A1 Isotopologues of lenalidomide
12/21/2011	EP2396311A2 Solid pharmaceutical composition comprising the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta(c)chromen-3-yl sulfamate and polymorphs thereof
12/21/2011	EP2396307A1 Novel amino azaheterocyclic carboxamides
12/21/2011	EP2396305A1 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione
12/21/2011	EP2396304A1 Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity
12/21/2011	EP2396303A2 Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide
12/21/2011	EP2396302A2 Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
12/21/2011	EP2396300A1 New substituted tetrahydronapthalenes, method for the production thereof, and use thereof as drugs
12/21/2011	EP2396298A1 Novel substituted indanes, method for the production thereof, and use thereof as drugs
12/21/2011	EP2396297A1 Androgen receptor modulating compounds, preparation and uses thereof
12/21/2011	EP2396296A1 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
12/21/2011	EP2396295A1 Phenoxy acetic acid derivatives
12/21/2011	EP2396083A2 Products comprising n-phenylpropenoyl amino acid amides and uses thereof
12/21/2011	EP2396082A2 Methods for treating hair related conditions
12/21/2011	EP2396070A2 Drug delivery through hydrogel plugs
12/21/2011	EP2396048A1 Method of treating vascular disease at a bifurcated vessel using a coated balloon
12/21/2011	EP2396034A1 Antibodies and methods for treating estrogen receptor-associated diseases
12/21/2011	EP2396029A1 Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
12/21/2011	EP2396027A2 Combined treatment of multiple sclerosis
12/21/2011	EP2396009A1 Compositions for the treatment of aphthous stomatitis
12/21/2011	EP2396008A1 Use of a chitosan polymer for heparin neutralization
12/21/2011	EP2396007A1 Methods for treating non-small cell lung cancer using 5-azacytidine
12/21/2011	EP2396006A1 High dosage doramectin formulation
12/21/2011	EP2396005A1 Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabete mellitus, impaired glucose tolerance or hyperglycemia
12/21/2011	EP2396004A1 Selective kinase inhibitors
12/21/2011	EP2396003A2 A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with a second anti-proliferative agent,
12/21/2011	EP2396002A2 (2.2.2) bicyclic derivatives and methods of use
12/21/2011	EP2396001A1 Par-1 antagonism in fed or antacid-dosed patients
12/21/2011	EP2396000A1 Combination vegfr2 therapy with temozolomide
12/21/2011	EP2395999A1 Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
12/21/2011	EP2395998A1 Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases
12/21/2011	EP2395997A1 Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers.
12/21/2011	EP2395996A1 Compounds and methods for inhibiting mmp2 and mmp9
12/21/2011	EP2395995A1 Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
12/21/2011	EP2395994A1 Foamable benzoyl peroxide compositions for topical administration
12/21/2011	EP2395993A1 Skin treatment
12/21/2011	EP2395992A2 Chemically programmed vaccination
12/21/2011	EP2395991A1 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
12/21/2011	EP2395990A1 Material and methods for treating developmental disorders including comorbid and idiopathic autism
12/21/2011	EP2395989A1 Treatment solution for treating wounds, in particular for liquid wound treatment
12/21/2011	EP2395988A2 Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
12/21/2011	EP2395987A1 Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
12/21/2011	EP2395986A1 Methods for preparing s1p receptor agonists and antagonists
12/21/2011	EP2395985A1 Antiseptic compositions comprising silver ions and menthol and uses thereof
12/21/2011	EP2395984A1 Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
12/21/2011	EP2395983A1 Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
12/21/2011	EP2395982A2 An implantable composite comprising a tacky biocompatible polymer film and a releasable bioactive agent
12/21/2011	EP2395980A1 Compositions and methods for treating post-operative pain using bupivacaine and an anti-inflammatory agent
12/21/2011	EP2395978A2 Device and method for producing pharmaceutically highly refined particles and for coating said particles in microreactors
12/21/2011	EP2395977A2 Liposomal citicoline injection
12/21/2011	EP2395976A2 Foamable microemulsion compositions for topical administration
12/21/2011	EP2395975A1 An oral pharmaceutical composition of dutasteride
12/21/2011	EP2395974A2 A composition for buccal absorption of nicotine for the purpose of smoking cessation
12/21/2011	EP2395971A2 N-hydroxylated amidine-, guanidine- and/or aminohydrazone-type prodrugs for application on the skin
12/21/2011	EP2395970A1 Valproic acid drug delivery systems and intraocular therapeutic uses thereof
12/21/2011	EP2395968A1 Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
12/21/2011	EP2395840A1 Controlled release pharmaceutical formulations of nitazoxanide
12/21/2011	EP2395839A1 Anti-fungal formulation
12/21/2011	EP2395837A1 Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
12/21/2011	EP2395835A1 Agonists and antagonists of the sip5 receptor, and methods of uses thereof
12/21/2011	EP2350005B1 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b
12/21/2011	EP2321295B1 4-(pyridin-4-yl)-1h-[1,3,5]triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
12/21/2011	EP2307382B1 Aminotetrahydroindazoloacetic acids
12/21/2011	EP2219647B1 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
12/21/2011	EP2217580B1 Substituted tetrazole compounds and uses thereof
12/21/2011	EP2211850B1 A system and method to improve sensory function
12/21/2011	EP2155736B1 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
12/21/2011	EP2155205B1 Treatment of meconium aspiration syndrome with estrogens
12/21/2011	EP2091922B1 2-[1-phenyl-5-hydroxy-4alpha-methyl-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
12/21/2011	EP2086951B1 Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
12/21/2011	EP2086925B1 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
12/21/2011	EP2079732B1 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist

1 ... 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 ... 7860